Literature DB >> 20629164

Parkinson's disease symptoms: the patient's perspective.

Marios Politis1, Kit Wu, Sophie Molloy, Peter G Bain, K Ray Chaudhuri, Paola Piccini.   

Abstract

Patients suffering from Parkinson's disease (PD) will typically experience a range of motor and nonmotor symptoms during the course of their illness, each of which will affect a particular individual to varying degrees. However, patients' perceptions of troublesome symptoms often differ from the clinician's view, and these discrepancies can hamper effective management of PD. In this study, we have assessed 265 consecutive PD patients by asking them to rank their three most troublesome symptoms in the last 6 months, so to gain further insight from the impact of illness on patients' quality of life. Patients were divided into early (<6 years) and late PD groups (>/=6 years) from symptom onset. The division at 6 years was based on the mean time from symptom onset to the development of motor complications. In the early PD group, the 5 most prevalent complaints (ranked in descending order) are slowness, tremor, stiffness, pain, and loss of smell and/or taste. In the advanced PD group, fluctuating response to their medication (most common: wearing-off phenomenon followed by dyskinesia), mood changes, drooling, sleep problems (most common: middle and late night insomnia followed by daytime sleepiness), and tremor were the top 5. Our findings provide further evidence for the diversity of experience in PD and suggest that as the disease advances the most troublesome issues that patients perceive are the lack of response to medication and the nonmotor aspects of the disease, highlighting the importance of assessment and patient-centered management in the follow-up of these patients.

Entities:  

Mesh:

Year:  2010        PMID: 20629164     DOI: 10.1002/mds.23135

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  129 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

2.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

Review 4.  Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease.

Authors:  Yazead Buhidma; Katarina Rukavina; Kallol Ray Chaudhuri; Susan Duty
Journal:  NPJ Parkinsons Dis       Date:  2020-01-06

Review 5.  Clinical features associated with drooling in Parkinson's disease.

Authors:  David Nascimento
Journal:  Neurol Sci       Date:  2021-01-14       Impact factor: 3.307

Review 6.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 7.  [Emergency medical training through simulation : Always the same for everyone?]

Authors:  A Schaumberg; T Schröder; M Sander
Journal:  Anaesthesist       Date:  2017-03       Impact factor: 1.041

8.  Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease.

Authors:  Carla Masala; Paolo Solla; A Liscia; G Defazio; L Saba; A Cannas; A Cavazzana; T Hummel; A Haehner
Journal:  J Neurol       Date:  2018-05-26       Impact factor: 4.849

Review 9.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 10.  Microglia-Mediated Inflammation and Neurodegenerative Disease.

Authors:  Ling Xu; Dan He; Ying Bai
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.